The FDA approved bemotrizinol (BEMT), a UV-filter ingredient long used in European and Asian sunscreens, marking the first new U.S. sunscreen ingredient since 1999.

BEMT, marketed as Parsol Shield, provides broad-spectrum UVA/UVB protection and is designed to reduce the white cast common with mineral sunscreens.

The agency says BEMT is safe for adults and children 6 months and older, with minimal skin irritation or absorption.

Experts from Yale, Mayo Clinic, and the Environmental Working Group discuss benefits, safety considerations, and improved options for consumers.

Analysts say SPF 30–50 offers optimal real-world protection, while higher SPF provides diminishing returns and requires reapplication.

Regulatory and consumer interest in better sunscreen options underscores ongoing concerns about efficacy, safety, and UV exposure.

The coverage includes regulatory achievement, anticipated consumer benefits, and reactions from advocacy groups and officials, with some partisan commentary interwoven.

dermatologists and analysts stress the importance of broad-spectrum protection and ongoing emphasis on reapplication and proper use.

U.S. sunscreens currently rely heavily on Avobenzone for UVA protection, which is unstable and often needs combinations; UVA protection is a key gap in many formulations.

EWG and experts note US products often underperform in UVA protection relative to labeled SPF, highlighting how BEMT could improve the market.

Only about 13% of American adults use sunscreen daily, suggesting that better-tasting or cosmetically appealing ingredients could boost adherence.

Experts from the Environmental Working Group expect bemotrizinol to fill a critical gap, offering effective and more cosmetically preferable protection.